Literature DB >> 17805057

Risk factors for recurrence and unfavorable prognosis in patients with stage I non-small cell lung cancer and a tumor diameter of 20 mm or less.

Naruyuki Kobayashi1, Shinichi Toyooka, Junichi Soh, Kouichi Ichimura, Hiroyuki Yanai, Hiroshi Suehisa, Shuji Ichihara, Masaomi Yamane, Motoi Aoe, Yoshifumi Sano, Hiroshi Date.   

Abstract

BACKGROUND: The purpose of this study was to identify risk factors for disease recurrence and unfavorable prognosis after surgical resection for stage I non-small cell lung cancer in patients with tumor diameters of < or =20 mm.
METHODS: One hundred sixty-three patients who had pathologic stage I non-small cell lung cancer with tumor diameters < or =20 mm and who had undergone a lobectomy with mediastinal lymph node dissection were retrospectively reviewed. The relationships between clinicopathologic factors and clinical outcomes, including recurrence and survival, were then examined. The clinicopathologic factors examined in this study were age, sex, smoking status, preoperative serum carcinoembryonic antigen level, pathologic tumor size, histologic subtype, histologic grade, and visceral pleural invasion.
RESULTS: Among the clinicopathologic factors that were examined, the histologic grade of the carcinoma status was significantly related to a high risk of recurrence when analyzed using univariate (p = 0.01) and multivariate analyses (p = 0.049). Regarding survival, patients with poorly differentiated carcinomas showed a significantly unfavorable overall survival (p < 0.001), disease-specific survival (p = 0.003), and disease-free survival (p = 0.002) compared with patients with well-/moderately differentiated carcinomas according to univariate analyses. A Cox proportional hazards model indicated that a poorly differentiated carcinoma status was the only independent factor for an unfavorable overall survival (p = 0.02), disease-specific survival (p = 0.046), and disease-free survival (p = 0.04).
CONCLUSIONS: Poor differentiation of tumor was the only risk factor for recurrence and an unfavorable prognosis for stage I non-small cell lung cancer patients with tumor diameters of < or =20 mm.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17805057     DOI: 10.1097/JTO.0b013e31814617c7

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  22 in total

1.  Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance).

Authors:  Linda W Martin; Jonathan D'Cunha; Xiaofei Wang; Debra Herzan; Lin Gu; Naif Abraham; Todd L Demmy; Frank C Detterbeck; Shawn S Groth; David H Harpole; Mark J Krasna; Kemp Kernstine; Leslie J Kohman; G Alexander Patterson; David J Sugarbaker; Robin T Vollmer; Michael A Maddaus; Robert A Kratzke
Journal:  J Clin Oncol       Date:  2016-02-29       Impact factor: 44.544

2.  Prognostic Factors for Post Recurrence Survival in Resected Pathological Stage I Non-small Cell Lung Cancer.

Authors:  Yasuaki Kubouchi; Yoshiteru Kidokoro; Takashi Ohno; Yohei Yurugi; Makoto Wakahara; Tomohiro Haruki; Hiroshige Nakamura
Journal:  Yonago Acta Med       Date:  2018-02-05       Impact factor: 1.641

Review 3.  International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Authors:  William D Travis; Elisabeth Brambilla; Masayuki Noguchi; Andrew G Nicholson; Kim R Geisinger; Yasushi Yatabe; David G Beer; Charles A Powell; Gregory J Riely; Paul E Van Schil; Kavita Garg; John H M Austin; Hisao Asamura; Valerie W Rusch; Fred R Hirsch; Giorgio Scagliotti; Tetsuya Mitsudomi; Rudolf M Huber; Yuichi Ishikawa; James Jett; Montserrat Sanchez-Cespedes; Jean-Paul Sculier; Takashi Takahashi; Masahiro Tsuboi; Johan Vansteenkiste; Ignacio Wistuba; Pan-Chyr Yang; Denise Aberle; Christian Brambilla; Douglas Flieder; Wilbur Franklin; Adi Gazdar; Michael Gould; Philip Hasleton; Douglas Henderson; Bruce Johnson; David Johnson; Keith Kerr; Keiko Kuriyama; Jin Soo Lee; Vincent A Miller; Iver Petersen; Victor Roggli; Rafael Rosell; Nagahiro Saijo; Erik Thunnissen; Ming Tsao; David Yankelewitz
Journal:  J Thorac Oncol       Date:  2011-02       Impact factor: 15.609

Review 4.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

Review 5.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

6.  Visceral Pleural Invasion in Pulmonary Adenocarcinoma: Differences in CT Patterns between Solid and Subsolid Cancers.

Authors:  Benedikt H Heidinger; Ursula Schwarz-Nemec; Kevin R Anderson; Constance de Margerie-Mellon; Antonio C Monteiro Filho; Yigu Chen; Marius E Mayerhoefer; Paul A VanderLaan; Alexander A Bankier
Journal:  Radiol Cardiothorac Imaging       Date:  2019-08-29

7.  Prognostic significance of grading in lung adenocarcinoma.

Authors:  Justine A Barletta; Beow Y Yeap; Lucian R Chirieac
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

8.  Risk of recurrence in surgically resected stage I adenocarcinoma of the lung: histopathologic and immunohistochemical analysis.

Authors:  Sukki Cho; Sook-Whan Sung; Sanghoon Jheon; Jin-Haeng Chung
Journal:  Lung       Date:  2008-10-04       Impact factor: 2.584

9.  The tumor-to-breast volume ratio (TBR) predicts cancer-specific survival in breast cancer patients who underwent modified radical mastectomy.

Authors:  Jiahuai Wen; Feng Ye; Xiaojia Huang; Shuaijie Li; Lu Yang; Xiangsheng Xiao; Xiaoming Xie
Journal:  Tumour Biol       Date:  2015-12-17

10.  A nomogram to predict overall survival of patients with early stage non-small cell lung cancer.

Authors:  Jiahui Zhang; Jingyi Fan; Rong Yin; Liguo Geng; Meng Zhu; Wei Shen; Yuzhuo Wang; Yang Cheng; Zhihua Li; Juncheng Dai; Guangfu Jin; Zhibin Hu; Hongxia Ma; Lin Xu; Hongbing Shen
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.